Reviva Pharmaceuticals Holdings Inc. Common Stock (RVPH)

FairStock Score: 68/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Reviva as a pre-revenue biotechnology speculation, not a proven business. It has 14 employees and a lead candidate, brilaroxazine, in neuropsychiatric illnesses. There is no revenue in the filed figures. Losses are large: net loss was $39.3 million in FY2023, the year ended 2023-12-31; $29.9 million in FY2024, the year ended 2024-12-31; and $19.9 million in FY2025, the year ended 2025-12-31. In fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $2.4 million, better than the $6.1 million net loss in fiscal Q2 2025, the quarter ended 2025-06-30, but still cash-consuming. Trailing free cash flow is negative $17.3 million, and FairStock calculates an FCF yield of -266.5% against the $6.5 million market cap on 2026-10-13. That is a ferocious burn relative to the equity value. The balance sheet has little debt, with D/E of 0.01, and the stock trades at 0.43 times book and a negative P/E of -0.48. But negative earnings make P/E meaningless, and book value is only a margin of safety if the cash is not spent. FairStock's Piotroski score of 1/9 and Altman Z-score of -11.05 confirm financial fragility. Return on equity is -176.60% and ROCE is -51.40%. The Lynch category is none because losses occurred in each of the last four years. A moat? None visible; the only potential moat is intellectual property and clinical success, which are unproven and binary. Valuation: the price looks statistically cheap at 0.43 times book, but Graham would demand proof of earning power or asset protection. Here, the asset is mostly future hope. The 52-week range of $0.26 to $15.40 shows extreme volatility. I would watch the science, the cash, and the share count, not the price alone.

In plain English: Reviva Pharmaceuticals is a very small biotech company trying to develop medicines for brain, breathing, inflammatory, and heart-related diseases. It has no product sales and has lost money every year, so the underlying business looks weak and unproven. The share price is low compared with its accounting book value, but because the company is burning cash, that low price does not make the business safe or clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer